Dipeptidyl Peptidase 4 Inhibition May Facilitate Healing of Chronic Foot Ulcers in Patients with Type 2 Diabetes

Table 2

Clinical and metabolic parameters before and 3 months after active treatment.

	Control group			Vildagliptin group
	Baseline	After 3 months	P	Baseline	After 3 months	P
			BMI (kg/m^2)			29.2 ± 2.8	28.3 ± 1.6	NS	30.1 ± 2.1	28.7 ± 1.2	NS
Systolic blood pressure (mmHg)	131 ± 18	130 ± 22	NS	129 ± 16	128 ± 20	NS
Diastolic blood pressure (mmHg)	79 ± 8	79 ± 10	NS	80 ± 7	78 ± 9	NS
Heart rate (bpm)	83 ± 26	81 ± 18	NS	84 ± 24	83 ± 21	NS
Laboratory results
Glycated hemoglobin (%)	8.0 ± 1.2	7.1 ± 1.2	<0.05	8.1 ± 1.3	7.0 ± 1.0	<0.05
Plasma glucose (mg/dL)	168 ± 23	126 ± 15	<0.05	170 ± 36	131 ± 12	<0.05
Creatinine (mg/dL)	1.1 ± 0.6	1.05 ± 0.2	NS	1.0 ± 0.8	1.0 ± 0.5	NS
Cholesterol (mg/dL)	230 ± 49	228 ± 33	NS	234 ± 51	233 ± 29	NS
Tryglicerides (mg/dL)	166 ± 63	155 ± 45	NS	171 ± 69	159 ± 44	NS
HDL (mg/dL)	36 ± 12	38 ± 9	NS	35 ± 11	39 ± 12	NS
LDL (mg/dL)	162 ± 23	159 ± 22	NS	165 ± 30	162 ± 26	NS
Transcutaneous oxygen tension (mmHg)	44.9 ± 12.1	45.8 ± 13.8	NS	44.2 ± 11.8	46.3 ± 13.2	NS
Wound area (cm^2)	4.1 ± 1.2	3.6 ± 2.1	NS	4.3 ± 1.5	1.2 ± 0.8*	<0.01

Data are means ± SD or n (%). *P < 0.05 compared to control group.